Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Olema Pharmaceuticals Inc shares valued at $268,800 were sold by Harmon Cyrus on Jan 20 ’26. At $26.88 per share, Harmon Cyrus sold 10,000 shares. The insider’s holdings dropped to 727,770 shares worth approximately $19.13 million following the completion of this transaction.
Also, Harmon Cyrus purchased 10,000 shares, netting a total of over 268,763 in proceeds.
Before that, Harmon Cyrus had sold 3,489 shares from its account. In a trade valued at $101,600, the Director traded Olema Pharmaceuticals Inc shares for $29.12 each. Upon closing the transaction, the insider’s holdings decreased to 3,489 shares, worth approximately $19.4 million.
As published in their initiating research note from Piper Sandler on January 07, 2026, Olema Pharmaceuticals Inc [OLMA] has been an Overweight and the price target has been revised to $40. Analysts at Guggenheim started covering the stock with ‘”a Buy”‘ outlook in a report released in early October. As of August 12, 2025, Citigroup has reiterated its “Buy” rating for OLMA. Earlier on April 02, 2024, Goldman initiated its rating. Their recommendation was “a Buy” for OLMA stock.
Analyzing OLMA Stock Performance
On last trading session, Olema Pharmaceuticals Inc [NASDAQ: OLMA] plunged -1.61% to $26.29. The stock’s lowest price that day was $25.825, but it reached a high of $26.78 in the same session. During the last five days, there has been a drop of approximately -5.74%. Over the course of the year, Olema Pharmaceuticals Inc shares have jumped approximately 364.49%.
Is Olema Pharmaceuticals Inc subject to short interest?
Stocks of Olema Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.41 million shares to 10.4 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 10.81 million shares. A decline of -3.96% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.94 of the overall float, the days-to-cover ratio (short ratio) decline to 3.94.
Which companies own the most shares of Olema Pharmaceuticals Inc (OLMA)?
In terms of Olema Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 43 in the next 12 months, up nearly 60.93% from the previous closing price of $26.72. Analysts anticipate Olema Pharmaceuticals Inc stock to reach 48 by 2026, with the lowest price target being 38. In spite of this, 3 analysts ranked Olema Pharmaceuticals Inc stock as Buy at the end of 2026. On January 30, 2024, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $20.
